Skip to main content
. 2014 Jun 16;289(33):23141–23153. doi: 10.1074/jbc.M114.562918

FIGURE 6.

FIGURE 6.

Sorafenib or B-Raf knockdown specifically reduces adhesion mediated by α4β1 integrin. A, parallel plate flow detachment assay of Jurkat cells incubated for 1 h with sorafenib (50 nm) and methanol vehicle control to slides coated with anti-α4β1 integrin mAb (19H8) or anti-CD28 mAb (1 μg/ml). B, percentage of cells incubated for 1 h with sorafenib (50 nm) and methanol vehicle control remaining at maximum shear to slides coated with anti-α4β1 integrin (19H8) (n = 8), anti-β1 integrin (33B6) (n = 6), anti-α5 integrin (n = 4), anti-LFA-1 (32E6) (n = 4), anti-LFA-1 (MHM24) (n = 3), anti-CD3 (OKT3) (n = 3), anti-CD4 (OKT4) (n = 3), anti-CD28 (n = 6), anti-CD43 (n = 3), anti-CD59 (n = 3), anti-GM1 (n = 3), or human ICAM-1 (5 μg/ml) (n = 6). C, percentage of B-Raf KD or vector control (VC) cells cultured with doxycycline (+D) remaining at maximum shear to slides coated with anti-α4β1 integrin (19H8) (n = 5), anti-LFA-1 (32E6) (n = 4), anti-CD3 (OKT3) (n = 4), or human ICAM-1 (5 μg/ml) (n = 6). Error bars, S.E. *, p < 0.01 using Student's t test.